Trade LXEO anytime, even after market hours
Regulated by
MAS
Trusted by
400,000+ users
Lexeo Therapeutics, Inc. (LXEO) is trading at US$4.86, down 2.61% today as of Aug 28, 16:00 EDT. The company has a market capitalisation of US$400.39M. Over the past 52 weeks, LXEO has traded between US$3.99 and US$10.99. On Syfe you can trade LXEO with $0 commission and add it to your watchlist.
| Previous close | US$4.99 |
|---|---|
| Market cap | US$400.39M |
| 52-week range | US$3.99 – US$10.99 |
| Volume | 663.6K |
| Exchange | US |
Add to Watchlist
Set Price Alert
Lexeo Therapeutics, Inc.
Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company, which engages in the development of therapies for hereditary and acquired diseases. The firm focuses on the medication of genetically defined cardiovascular diseases and sub-group of Alzheimer’s disease. It offers LX2006 for the treatment of patients with Friedreich's ataxia, cardiomyopathy, and LX1001 for APOE4 homozygous patients with Alzheimer's disease. The company was founded by Ronald G. Crystal in February 2017 and is headquartered in New York, NY.
Year: 2023
Lexeo Therapeutics Finalizes Study Design for Friedreich Ataxia Gene Therapy
Jun 15, 1:29 PM · MT Newswires
Lexeo Therapeutics, Inc. (LXEO) stock is trading at US$4.86, -2.61% from the previous close of US$4.99.
The market cap for Lexeo Therapeutics, Inc. (LXEO) stock is approximately US$400.39M.
The 52-week high for Lexeo Therapeutics, Inc. (LXEO) stock is US$10.99.
The 52-week low for Lexeo Therapeutics, Inc. (LXEO) stock is US$3.99.
Lexeo Therapeutics, Inc. (LXEO) does not currently pay a dividend.
Stay on top of LXEO
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
